|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 912 East Capitol Street NE |
Address2 |
|
City | Washington |
State | DC |
Zip Code | 20001 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 401105617-51
|
||||||||
|
6. House ID# 447300005
|
TYPE OF REPORT | 8. Year | 2023 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Elizabeth Karan |
Date | 10/20/2023 3:19:27 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Appropriations for the National Breast and Cervical Cancer Early Detection Program
Appropriations for breast cancer research
Appropriations for cancer prevention and control
Policies related to access to supplemental and diagnostic breast imaging
FY24 House and Senate Labor-HHS Appropriations bills
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, White House Office, Office of Science & Technology Policy (OSTP), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Johanna |
Gray |
|
Intern, Senator Barack Obama |
|
Elizabeth |
Karan |
|
|
|
Leslie |
Brady |
|
Health Policy Advisor/Legislative Assistant, Rep. Brian Higgins |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code INS
16. Specific lobbying issues
Access to Breast Cancer Diagnosis (ABCD) Act (H.R.3851/S. 2464)
Cancer Drug Parity Act (S. 2039)
Telehealth Benefit Expansion for Workers Act (H.R. 824)
Association Health Plans Act (H.R. 2868)
Safe Step Act (H.R.2630/S. 652)
Implementation of the Affordable Care Act
Policies related to insurance coverage and COVID-19
HELP Copays Act (H.R.830/S.1375)
Cancer survivorship issues
Issues related to prescription drug affordability for patients
Administrative actions necessary to reduce out-of-pocket costs for medical-necessary diagnostic breast imaging
Congressional action to reduce out-of-pocket costs for medically necessary diagnostic breast imaging
Issues related to regulation of short-term limited duration plans
Implementation of the No Surprises Act
Find It Early Act (H.R.3086); a bill to provide for health coverage with no cost-sharing for additional breast screenings for certain individuals
Policies related to coverage of preventive services with no cost-sharing
Polices regarding White House Cancer Moonshot implementation
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Internal Revenue Service (IRS), Labor - Dept of (DOL), Office of Personnel Management (OPM), Office of Science & Technology Policy (OSTP), Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Johanna |
Gray |
|
Intern, Senator Barack Obama |
|
Elizabeth |
Karan |
|
|
|
Leslie |
Brady |
|
Health Policy Advisor/Legislative Assistant, Rep. Brian Higgins |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Metastatic Breast Cancer Access to Care Act (S. 663 / HR 549)
Reducing Hereditary Cancer Act (HR 1526/S. 765)
CONNECT for Health Act (H.R. 4189/S. 2016)
Medicare coverage policy for breast cancer treatments and services
Telehealth
Policies related to funding, state incentives, and federal efforts for Medicaid expansion
Issues related to 1115 and 1332 of the Social Security Act; policies related to work requirements, reinsurance and block grants in Medicaid
Policies related to Medicare coverage for pharmacy services
Medicare coverage policy for drugs and drug pricing
H.R. 9505 - Find It Early Act; a bill to provide for health coverage with no cost-sharing for additional breast screenings for certain individuals
Medicaid unwinding, the process for redetermination of Medicaid eligibility
Medicare Drug Pricing Negotiation implementation
Implementation of Lymphedema Treatment Act
Preserving and expanding access to Medicaid
Comments in response to the Medicare CY24 Physician Fee Schedule Proposed Rule
Comments in response to the Medicare CY24 Hospital Outpatient Prospective Payment System
Comments in response to Medicare Program; Calendar Year (CY) 2024 Home Health (HH) Prospective Payment System Rate Update; HH Quality Reporting Program Requirements; HH Value-Based Purchasing Expanded Model Requirements; Home Intravenous Immune Globulin Items and Services; Hospice Informal Dispute Resolution and Special Focus Program Requirements, Certain Requirements for Durable Medical Equipment Prosthetics and Orthotics Supplies; and Provider and Supplier Enrollment Requirements (CMS-1780-P)
Comments in response to Solicitation of Comments on Maximum Monthly Cap on Cost-Sharing Payments Under Prescription Drug Plans: Draft Part One Guidance on Select Topics, Implementation of Section 1860D-2 of the Social Security Act for 2025
Comments in response to CMS-2434-P; Medicaid Program; Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Johanna |
Gray |
|
Intern, Senator Barack Obama |
|
Elizabeth |
Karan |
|
|
|
Leslie |
Brady |
|
Health Policy Advisor/Legislative Assistant, Rep. Brian Higgins |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Health disparities
Access to clinical trials for underrepresented populations
Policies related to cancer survivorship
Policies related to medications access in during emergencies
Polices related to PBM and drug cost transparency
Policies related to COVID-19 vaccination distribution
Policies impacting immunocompromised people, including COVID-19 vaccination and monoclonal antibody distribution
Policies related to reducing the cost of cancer treatment for patients
Policies related to decline in breast cancer screenings during the COVID-19 pandemic
Policies related to genetic counseling and screening
Screening for Communities to Receive Early and Equitable Needed Services for Cancer Act; a bill to amend the Public Health Service Act to reauthorize and improve the National Breast and Cervical Cancer Early Detection Program for fiscal years 2024 through 2028 (H.R.3916/S.1840)
Policies related to the implementation of the Breast Density and Mammography Reporting Act of 2017 and the 2023 Final Rule Amending Part 900 of the Mammography Quality Standards Act
Policies related to administrative actions necessary in breast imaging and breast cancer diagnosis
Policies related to the regulation of diagnostic devices
Better Empowerment Now to Enhance Framework and Improve Treatments Act of 2021 or the BENEFIT Act of 2021, requiring the Food and Drug Administration (FDA) to consider relevant patient-focused drug development data, such as data from patient preference studies and patient-reported outcome data, in the risk-benefit assessment framework used in the process for approving new drugs (S.373/ H.R.4472)
Palliative Care and Hospice Education Training Act (PCHETA) (S. 2243)
Comments in response to the discussion draft of the Stop Drug Shortages Act
Letter to Congressional leadership related to drug shortages
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Johanna |
Gray |
|
Intern, Senator Barack Obama |
|
Elizabeth |
Karan |
|
|
|
Leslie |
Brady |
|
Health Policy Advisor/Legislative Assistant, Rep. Brian Higgins |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
H.R. 3503/S. 1701 - NIH Clinical Trial Diversity Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Elizabeth |
Karan |
|
|
|
Johanna |
Gray |
|
Intern, Senator Barack Obama |
|
Leslie |
Brady |
|
Health Policy Advisor/Legislative Assistant, Rep. Brian Higgins |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |